Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pomalidomide Celgene

- PMLiVE

Celgene’s apremilast set for 2013 filing

Pharma company releases positive phase III results for psoriasis candidate

Novartis building

Novartis’ Jakavi turned down by NICE for blood cancer

UK cost-effectiveness watchdog concerned about 'uncertainties' in data in draft guidance

- PMLiVE

Interview: Cesar Rodriguez, Janssen

Managing director of Janssen UK & Ireland, Cesar Rodriguez is relishing being in the UK market, after years working across Europe and North Africa

- PMLiVE

Celgene gets US green light for blockbuster candidate Pomalyst

FDA approval to treat multiple myeloma

- PMLiVE

Actavis mounts patent challenge on Velcade in US

Plans to launch own version of Takeda’s cancer drug

- PMLiVE

Sarah Bater joins Celgene

Will head human resources in UK and Ireland

- PMLiVE

Celgene signs $500m antibody deal with Sutro

Joins list of companies with interest in antibody-drug conjugates

- PMLiVE

Celgene wins 2012 PMEA for excellence in ongoing brand management

Also receives recognition for internal capability development and orphan drug Vidaza

Celgene’s Abraxane receives FDA approval in lung cancer

Adds to current breast cancer indication

European approvals for J&J cancer treatments

EC passes new Dacogen indications and backs subcutaneous Velcade

- PMLiVE

Interview: Sam Pearce, Celgene

The general manager of Celgene UK and Ireland explains to Liz Wells how her entrepreneurial spirit fits well with this fast-expanding biotech

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links